Raymond James Financial
SPRY icon

Raymond James Financial’s ARS Pharmaceuticals SPRY Stock Holding History

Raymond James Financial’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.55M Sell
318,583
-206,641
-39% -$1.78M ﹤0.01% 3312
2026
Q1 		$4.22M Sell
525,224
-40,832
-7% -$391K ﹤0.01% 2734
2025
Q4 		$6.59M Sell
566,056
-190,291
-25% -$1.85M ﹤0.01% 2289
2025
Q3 		$7.6M Buy
756,347
+82,977
+12% +$1.19M ﹤0.01% 2139
2025
Q2 		$11.8M Sell
673,370
-33,417
-5% -$482K ﹤0.01% 1744
2025
Q1 		$8.89M Buy
706,787
+83,506
+13% +$1M ﹤0.01% 1905
2024
Q4 		$6.58M Buy
+623,281
New +$8.73M ﹤0.01% 2146

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Raymond James Financial's SPRY Position: Q2 2026 in Review

Raymond James Financial reduced its ARS Pharmaceuticals (SPRY) stake by 39% in Q2 2026, selling an estimated $1.78M and leaving 318,583 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #3312.

Raymond James Financial first reported a position in SPRY in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.8M in Q2 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Raymond James Financial held 318,583 shares of ARS Pharmaceuticals worth $2.55M as of Q2 2026.
  • Raymond James Financial sold 206,641 ARS Pharmaceuticals shares in Q2 2026, an estimated $1.78M.
  • ARS Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3312 holding.
  • Raymond James Financial first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's ARS Pharmaceuticals position peaked at $11.8M in Q2 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.